Illumina (ILMN)
(Delayed Data from NSDQ)
$131.20 USD
-3.19 (-2.37%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $131.08 -0.12 (-0.09%) 7:58 PM ET
1-Strong Buy of 5 1
D Value C Growth F Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ILMN 131.20 -3.19(-2.37%)
Will ILMN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ILMN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ILMN
Longboard Stock Soars on FDA Designations for Epilepsy Drug
J&J's Rybrevant Receives FDA Nod for Expanded Use in NSCLC
ILMN: What are Zacks experts saying now?
Zacks Private Portfolio Services
VNDA Stock Down as FDA Rejects NDA for Tradipitant in Gastroparesis
GSK Meets Study Goal for Co-Administered RSV-Shingles Vaccines
EWTX Stock Soars on Upbeat Efficacy Data From Cardiomyopathy Studies
Other News for ILMN
10 Health Care Stocks With Whale Alerts In Today's Session
BIOSECURE Act passage would be modest positive for Illumina, says Canaccord
GRAIL's Potential Turnaround: Seeking FDA Approval For Galleri
Tracking Carl Icahn's 13F Report - Q2 2024 Update
Illumina files for potential mixed shelf